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Steroid hormones: Interactions with membrane-bound receptors
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Steroid hormones are generally thought to pass easily
across a plasma membrane into a cell, interacting once
inside with soluble nuclear receptors, but recent
experiments have demonstrated the importance of
membrane-bound receptors in mediating the activity
and the metabolism of steroid hormones.
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Hormones traditionally have been classified into two
major groups: hydrophilic peptides or amino acid deriva-
tives, which exert their actions via membrane-bound
receptors; and hydrophobic, cholesterol-derived steroids,
which diffuse across the cellular membrane and act on
receptors at the nuclear level. Such categorization,
however, is likely to be an oversimplification. Recent
studies suggest that steroid hormones use receptors on
cellular membranes both to gain access to the intracellular
compartment and to modulate cellular functions. These
interactions with cell-surface receptors have important
physiological consequences.
The classical model of steroid hormone action
Clever and Karlson [1] first showed that steroid hormones
act at the genomic level in 1960, when they showed that
ecdysone can induce ‘puffs’ on giant insect chromosomes.
Subsequent observations revealed that a fundamental
action of steroid hormones — the induction of protein
synthesis — correlated with apparent changes in gene
transcription (reviewed in [2]). The implication was that
the chromosome puffs are formed as a consequence of the
transcriptional activation of specific genes. Intracellular
receptors for steroid hormones were subsequently identi-
fied, beginning in the 1960s, and genes encoding many of
them were cloned in the 1980s and 1990s.
These discoveries were the origins of the classical model
for steroid hormone action (Figure 1a). In this model, the
hydrophobic steroid hormones are transported in the circu-
lation largely bound to plasma carrier proteins. The bound
hormones are biologically inactive. According to the ‘free
hormone hypothesis’ (reviewed in [3]), steroid hormones
exert their effects after dissociating from the carrier pro-
teins. It is thought that, because of their lipophilic nature,
free steroid hormones enter target cells primarily by
passive diffusion through the cell membrane. After gaining
entry to the cell, steroid hormones act as ligands for nuclear
receptors and alter gene transcription (reviewed in [4]).
A cell-surface receptor for a steroid hormone
Passive diffusion of steroid hormones across cell mem-
branes does not, however, adequately explain several
observations regarding the cellular uptake of steroid
hormones. Kinetic studies of steroid hormone metabolism,
such as those for vitamin D, have suggested that the non-
specific diffusion of free hormones across cell membranes
cannot fully account for their clearance rates from the
serum [5]. Furthermore, some steroid target tissues
express binding sites for carrier proteins (reviewed in [6]),
and certain human breast cancer cells can internalize
testosterone/estradiol-binding protein by receptor-medi-
ated endocytosis [7]. These findings have suggested that
receptor-mediated uptake of steroid hormones, bound to
their carrier proteins, may play a role in steroid metabo-
lism, although the physiological significance of such path-
ways has been unclear.
A recent study by Willnow and colleagues [8] alters our
view of steroid hormone metabolism by demonstrating both
the existence and the biological importance of a receptor-
mediated endocytosis pathway for a steroid-like hormone in
its carrier-protein-bound state. These researchers studied
‘knockout’ mice lacking megalin, a membrane receptor that
is a member of the low density lipoprotein (LDL) receptor
family and is expressed on the apical surfaces of several
epithelial cell types, including those in the choroid plexus
and the proximal tubule of the kidney. Like several other
members of the LDL receptor family, megalin has rela-
tively broad ligand-binding specificity and mediates the
cellular uptake of a number of macromolecules. 
Although most megalin–/– mice die perinatally because of
defective forebrain development [9], approximately one in
fifty survive to adulthood. It was these mice, which exhibit
severe bone malformation and dramatically reduced bone
density, that Nykjaer et al. [8] studied. Because megalin
had previously been shown to be capable of taking up mol-
ecules injected into proximal renal tubules, and because
electron microscopy of kidneys from megalin–/– mice
demonstrated fewer endocytic organelles than normal, the
researchers hypothesized that megalin–/– mice may be
unable to resorb certain macromolecules from the urine. 
To test this hypothesis, Nykjaer et al. [8] performed a
simple but key experiment — they compared the urinary
proteins of megalin–/– mice with those of wild-type mice
by using sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis. They found that several low-molecular-
weight proteins were present only in the urine of the
megalin–/– mice. One of these proteins was identified as
vitamin D-binding protein, the principal carrier protein for
vitamin D in the serum. The investigators went on to
show that urinary excretion of vitamin D-binding protein
and 25-(OH) vitamin D3 was markedly increased in
megalin–/– mice, and there was an accompanying 80%
reduction of plasma 25-(OH) vitamin D3. Moreover,
similar changes could be induced in rats by infusing
kidney tubules with receptor-associated protein, a protein
that binds to megalin and other LDL-receptor family
members and prevents them from binding ligands.
Megalin deficiency also decreased the conversion of
25-(OH) vitamin D3 to its active metabolite, 1,25-(OH)2
vitamin D3, a process that is catalyzed by a mitochondrial
hydroxylase in proximal tubular cells. This effect was also
produced by infusion of receptor-associated protein in
rats. Perfusing rats with tracer-labeled 25-(OH) vitamin
D3 bound to vitamin D-binding protein resulted in the
recovery of tracer-labeled 1,25-(OH)2 vitamin D3 from the
serum; in contrast, no tracer-labeled dihydroxylated prod-
ucts were detected in the plasma or the urine of animals
co-infused with receptor-associated protein. Thus, the
lack of megalin causes both decreased serum levels of
25-(OH) vitamin D3 and deficiency of 1,25-(OH)2 vitamin
D3 conversion. The resultant severe vitamin D deficiency
apparently accounts for the skeletal deformities and
decreased bone density in megalin–/– mice.
Taken together, these experiments show that vitamin D,
a steroid-like hormone, is taken up in its vitamin
D-binding protein-bound state into renal tubular cells via
the endocytic receptor megalin, and that the receptor is
necessary to maintain normal vitamin D homeostasis.
Without this mechanism, there are defects in both the
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Steroid hormone
Three ways that a steroid hormone can interact with a cell. (a) The
classical model. The steroid hormone dissociates from its plasma
carrier protein and diffuses across the cell membrane. After gaining
entry to the cell, the free hormone binds to an intracellular receptor and
alters gene transcription. (b) Receptor-mediated endocytosis. The
steroid hormone, bound to its plasma carrier protein, is brought into
the cell via a cell-surface receptor. The complex is broken down inside
the lysosome, and free steroid hormone diffuses into the cell, where it
subsequently exerts its action at the genomic level or undergoes
metabolism. (c) Signalling through cell-surface receptors. The free
steroid hormone alters intracellular signalling by binding to cell-surface
receptors. The steroid hormone could exert these effects directly or
could alter signalling by blocking the actions of peptide hormones.
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studies demonstrate that a receptor-mediated endocytosis
pathway not only exists for a steroid-like hormone but
also plays a crucial role in the hormone’s activity and
metabolism (Figure 1b).
Membrane receptors in steroid hormone action
Evidence is accumulating that cell-membrane receptors
can not only take up steroid hormones through endocyto-
sis, but also mediate steroid hormone action directly in
some cases. Steroid hormones sometimes elicit extremely
fast cellular responses (within seconds to minutes), which
are too rapid to be attributed to induced RNA or protein
synthesis. In the late 1960s, Szego et al. [10] showed that
estrogen acutely raised cyclic AMP levels in rat uterus;
several years later, Pietras et al. [11] identified specific
binding sites for estrogen at the outer surfaces of isolated
endometrial cells. Since then, steroid hormone action has
been implicated in the opening and closing ion channels,
the generation of second messengers, and the phosphory-
lation of transcription factors (reviewed in [12]), all
independent of any action at the genomic level.
How do steroid hormones act at the cell membrane? One
way seems to involve direct binding of steroids to recep-
tors of peptide hormones. Grazzini et al. [13] have
recently elucidated the mechanism by which proges-
terone, a steroid hormone essential for maintaining mam-
malian pregnancy, can effect uterine quiescence without
changing gene expression or protein synthesis. They
found that progesterone directly inhibited the activity of
oxytocin, a peptide capable of inducing uterine contrac-
tions, by binding to cell-surface oxytocin receptors. This
action of progesterone reduced two functional conse-
quences of oxytocin signalling: production of the second
messenger inositol-1,4,5-triphosphate and an increase in
intracellular calcium concentration. These results there-
fore illustrate another mechanism of steroid hormone
action — the modulation of signalling through cell-
surface receptors (Figure 1c). In some instances, steroid
hormones might also bind specifically to cell-surface
steroid hormone receptors [14].
Why are there multiple pathways of steroid action?
Why should steroid hormones interact with receptors both
at the cell surface and in the nucleus? Szego [15] has
suggested that the synthesis of macromolecules as a result
of genomic actions of steroid hormones must be preceded
by rapid changes in the cellular environment to ‘prime’
the cell and support such activity. These preparative
changes may include altered ion influxes, import of amino
acids and sugars, or phosphorylation of key enzymes, all of
which could be triggered by interactions of steroid
hormones with cell-surface receptors.
The interaction of steroid hormones with endocytic
receptors could serve to target steroids to specific cell
types in order to augment their effects or metabolism. In
contrast to the classical model, in which steroid hormones
diffuse into target tissues in a non-specific fashion, recep-
tor-mediated endocytosis could serve to concentrate
steroid hormones in particular cell types, thereby increas-
ing hormonal activity at the target tissues without expos-
ing the rest of the organism to equally high levels of the
hormone. Alternatively, as shown for vitamin D and
megalin, receptor-mediated endocytosis of the carrier
protein–steroid hormone complex might target a hormone
to a specific cell type that is important for its metabolism.
Perspectives
Recent advances have demonstrated the importance of
membrane-bound receptors in mediating the activity and
the metabolism of steroid hormones. These new discover-
ies raise a number of questions. Are the cases discovered
above isolated findings, or are many steroid hormones
capable of interacting with cell-surface receptors? If so,
which steroids and receptors are involved, and what roles
do these interactions play in their actions or metabolism?
These advances may also have important medical implica-
tions. For example, these receptor–steroid interactions
might provide new sites for therapeutic interventions:
perhaps a compound that solely antagonizes the receptor-
mediated uptake of bound steroid hormones would be
more efficacious or cause fewer side effects than a non-
selective steroid antagonist. Functional studies of specific
receptors may provide answers to these questions.
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If you found this dispatch interesting, you might also want
to read the April 1999 issue of
Current Opinion in
Cell Biology
which included the following reviews, edited
by Joan S Brugge and Frank McCormick,
on Cell regulation:
Regulation of tyrosine kinase cascades by G-protein-
coupled receptors
Louis M Luttrell, Yehia Daaka and Robert J Lefkowitz
Epidermal growth factor receptors: critical mediators
of multiple receptor pathways
Peter O Hackel, Esther Zwick, Norbert Prenzel 
and Axel Ullrich
Multiple positive and negative regulators of signaling
by the EGF-receptor
Nadeem Moghal and Paul W Sternberg
Interactions between mitogenic stimuli, or, a thousand
and one connections
Martin A Schwartz and Veronique Baron
Costimulatory regulation of T cell function
Cynthia A Chambers and James P Allison
Organization and regulation of mitogen-activated
protein kinase signaling pathways
Timothy P Garrington and Gary L Johnson
Signalling through phosphoinositide 3-kinases: the
lipids take centre stage
Sally L Leevers, Bart Vanhaesebroeck 
and Michael D Waterfield
Multiple signals converging on NF-κB
Frank Mercurio and Anthony M Manning
Regulation of LEF-1/TCF transcription factors by Wnt
and other signals
Quinn Eastman and Rudolf Grosschedl
In or out? Regulating nuclear transport
Jennifer K Hood and Pamela A Silver
Organization and regulation of proteins at synapses
Jee Hae Kim and Richard L Huganir
Apoptosis control by death and decoy receptors
Avi Ashkenazi and Vishva M Dixit
Deciphering the pathways of life and death
Honglin Li and Junying Yuan
Regulating the onset of mitosis
Ryoma Ohi and Kathleen L Gould
The full text of Current Opinion in Cell Biology is in the
BioMedNet library at
http://BioMedNet.com/cbiology/cel
